Clinical Trial

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Name: Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC) — clinical trial record (NCT07092514)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This open-label, randomized phase II trial evaluates the dose delivery, tolerance, and efficacy of two dosing regimens of lenvatinib among patients with radioactive iodine resistant (RAIR) differentiated thyroid cancer (DTC).

Trial Details

NCT Number	NCT07092514
Lead Sponsor	Washington University School of Medicine
Conditions	Thyroid Cancer, Cancer of the Thyroid
Enrollment	34 participants
Start Date	2025-10-14
Primary Completion	2029-04-17 (estimated)
Study Completion	2034-10-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-17